Bioceltix S.a.
Warsaw Stock ExchangeTotal Valuation
Bioceltix S.a. carries a market capitalization of 497.90M, placing it among publicly traded companies globally. Its enterprise value stands at 338.89M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 497.90M |
| Enterprise Value | 338.89M |
Share Statistics
Bioceltix S.a. currently has 5.53M shares outstanding.
| Shares Outstanding | 5.53M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -20.05 |
| P/TBV Ratio | 5.91 |
| P/FCF Ratio | -27.73 |
| P/OCF Ratio | -22.75 |
Financial Position
Bioceltix S.a. maintains a current ratio of 22.56, meaning it holds 22.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.35, indicating conservative leverage, while an interest coverage ratio of -146.35 demonstrates limited ability to service its debt obligations.
| Current Ratio | 22.56 |
| Quick Ratio | 21.07 |
| Debt / Equity | 0.35 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | -146.35 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -31.27 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | -41,289.41 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Bioceltix S.a.'s stock has declined approximately -10.35857% over the past 52 weeks. The 50-day moving average sits at 86.49, while the 200-day moving average is 86.79.
| Beta (5Y) | N/A |
| 52-Week Price Change | -10.35857% |
| 50-Day Moving Average | 86.49 |
| 200-Day Moving Average | 86.79 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -17.33M, while operating income came in at -17.33M.
| Revenue | N/A |
| Gross Profit | -2.64M |
| Operating Income | -17.33M |
| Pretax Income | -17.23M |
| Net Income | -17.18M |
| EBITDA | -17.33M |
| EBIT | -17.33M |
| Earnings Per Share (EPS) | -3.29 |
Balance Sheet
Bioceltix S.a. holds 60.79M in cash and equivalents against 235,301.34 in total debt, resulting in a net debt position of -60.79M. Total book value stands at -19.92M, with working capital of 62.20M providing operational flexibility.
| Cash & Cash Equivalents | 60.79M |
| Total Debt | 235,301.34 |
| Net Debt | -60.79M |
| Equity (Book Value) | -19.92M |
| Book Value Per Share | -3.81 |
| Working Capital | 62.20M |
Cash Flow
Bioceltix S.a. produced -17.56M in operating cash flow over the past twelve months. After subtracting -3.15M in capital expenditures, free cash flow totaled -20.71M - equivalent to -3.96 per share.
| Operating Cash Flow | -17.56M |
| Capital Expenditures | -3.15M |
| Free Cash Flow | -20.71M |
| FCF Per Share | -3.96 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -12.25 |
| FCF Yield | -3.61 |
Scores
Bioceltix S.a. posts an Altman Z-Score of 79.10, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 79.10 |